Measurable Residual Disease in AML using Oncomine NGS analysis

Sponsored by: Thermo Fisher Scientific
Speaker

Abstract
The presentation "Measurable Residual Disease in AML using Oncomine NGS analysis" by Dr. Jong-Mi Lee from the College of Medicine at The Catholic University of Korea explores the application of next-generation sequencing (NGS) in tracking measurable residual disease (MRD) in acute myeloid leukemia (AML) research. It delves into the dynamics of MRD, the identification of leukemia-associated fusions and mutations, and the characterization of clones in childhood AML. The study compares the Oncomine Myeloid MRD RUO Assay (OMA-MRD) to digital PCR, highlighting the assay's sensitivity and potential in clinical research for improving MRD detection.
 
Learning Objectives
  • Gain a deeper understanding of the diverse applications of next-generation sequencing (NGS) in clinical oncology research
  • Explore the latest important biomarkers in clinical oncology research, such as HRD and
  • Uncover the remarkable ease, simplicity, and speed at which NGS can revolutionize your work, while acquiring valuable tools to explore its vast possibilities
 
 
Webinars will be available for unlimited on-demand viewing after live event.
 
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

You May Also Like
Loading Comments...